However, four metastatic breast cancer samples (hepatic metastasis and supraclavicular, pleural, hilar, and lymph nodes) infiltrated by the primary breast IDC tumor, and two patient-derived tumor xenograft (PDX) models (derived from supraclavicular and hilar metastases) showed loss of heterozygosity (LOH) in BRCA2 (Table 1, Fig. 3E–F and Figure S1B–E). This evidence concerns the gene BRCA2 and medical procedure.